在估值层面，核心医疗成立以来已完成 6 轮融资。2025 年 4 月，公司完成 D 轮融资，对应估值约 35.45 亿元；2025 年 8 月发生的股权转让， 对应估值约 33.88 亿元 。 在第五套上市标准"预计市值不低于 40 亿元"的要求下，其最终能否满足市值门槛，仍有待市场与发行环节进一步验证。 财务方面， 公司目前尚未实现盈利 。2022—2024 年及 2025 年上半年，核心医疗营业收入分别为 0 元、1655.03 万元、9368.84 万元和 7047.76 万元；同期归 母净利润分别为 -1.78 亿元、-1.70 亿元、-1.32 亿元和 -7275.14 万元。 2026年2月2日，上交所官网显示， 深圳核心医疗科技股份有限公司 科创板 IPO 申请状态更新为 "已问询" 。 核心医疗的 IPO 申请于 2025 年 11 月 6 日获受理，保荐机构为 华泰联合证券 。公司采用 科创板第五套上市标准申报 ，是该标准重启后，以创新医疗器械为主营 方向进入审核阶段的代表性企业之一。 招股书显示，核心医疗成立于 2016 年，主要从事人工心脏及机械循环辅助装置等高端创新医疗器械的研发与产业 ...

Core Viewpoint - Shenzhen Core Medical's IPO application has been accepted, marking the first innovative medical device company to be accepted under the newly restarted fifth standard of the Sci-Tech Innovation Board [1] Company Overview - Core Medical specializes in artificial hearts, with its flagship product, Corheart 6, being the fourth approved artificial heart in China and the latest domestic product to market as of June 2023 [1] - Corheart 6 has achieved a national market share exceeding 45% by 2024, making it the leading product in the industry [1][4] - The company has undergone six rounds of financing, attracting investments from notable institutions such as Hillhouse Capital and Zhengxin Valley [1] Market Dynamics - The primary application of artificial hearts is in heart failure, with over 15 million heart failure patients in China by 2024, including over 1.5 million in end-stage heart failure [2] - The number of heart transplants in China is limited, with only 1,064 procedures performed in 2024, leading many patients to opt for artificial hearts as a transitional or long-term solution [2] Product Performance - Corheart 6 has become the most implanted artificial heart in China, achieving over 1,000 implants, making it the second globally to reach this milestone after Abbott's HeartMate 3 [1][4] - The product is noted for being the smallest and lightest magnetic levitation implantable artificial heart, which facilitates smaller surgical incisions and faster patient recovery [5][6] Financial Aspects - The gross margin for artificial hearts remains above 72%, with the average factory price of Corheart 6 decreasing from 290,000 yuan in 2023 to nearly 230,000 yuan by 2025 [7] - Recent policy changes have included artificial hearts in medical insurance reimbursement lists, significantly reducing out-of-pocket costs for patients [7] Future Developments - Core Medical is developing the world's first magnetic levitation dual-heart assist device, DuoCor 2, which is currently in clinical evaluation and expected to enter special review procedures in November 2024 [9] - The company is also working on an interventional artificial heart product, CorVad, anticipated to be the first approved interventional artificial heart in China by the first quarter of 2026 [9]